What Is the EDAS Procedure for Moyamoya Disease?

Encephaloduroarteriosynangiosis, or EDAS, is a surgical procedure that redirects blood flow to the brain by transplanting a scalp artery onto the brain’s surface, coaxing the body into growing new blood vessels over the following months. It belongs to a family of “indirect” revascularization surgeries, meaning the surgeon does not stitch two arteries together. Instead, the procedure relies on the brain’s own capacity to sprout collateral vessels from a donated blood supply laid against its outer layers. Developed primarily for moyamoya disease, EDAS has found a widening role in other conditions where major brain arteries narrow or close off, and the science around why it works in some patients better than others is still evolving.

What Happens During the Surgery

The name itself is a roadmap of the anatomy involved. “Encephalo” refers to the brain, “duro” to the dura mater (the tough membrane covering the brain), and “arterio-synangiosis” to the connection formed between an artery and brain tissue. In practice, the surgeon identifies the superficial temporal artery, a vessel running just beneath the skin of the temple. A segment of this artery is carefully freed from the surrounding tissue while keeping its blood flow intact, then laid directly onto the surface of the exposed brain after the dura is opened. The dura is then closed over the artery, sandwiching it between the brain and its protective membrane.¹

Over the following weeks and months, the brain essentially “recruits” blood from this newly positioned artery. Tiny new vessels grow from the transplanted artery into the brain’s surface tissue. This process is gradual, which is a key distinction from direct bypass surgery, where a surgeon hand-stitches an outside artery directly to a brain artery and blood flow improves immediately on the operating table. With EDAS, the payoff is delayed but unfolds organically as the brain’s own biology does the plumbing work.

In pediatric patients, EDAS and related indirect techniques are often preferred over direct bypass because a child’s blood vessels are simply too small to suture reliably.² The trade-off is that full revascularization takes longer, and the brain remains somewhat vulnerable during the window before new collateral vessels mature.

Why It Exists: Moyamoya Disease

The overwhelmingly common reason someone undergoes EDAS is moyamoya disease, a condition in which the large arteries at the base of the brain slowly narrow and eventually close off. The body tries to compensate by growing a fragile tangle of tiny collateral vessels, which Japanese researchers described as looking like “a puff of smoke” on imaging, hence the name moyamoya. These natural collaterals are insufficient and unstable, leaving patients vulnerable to strokes, both ischemic (from blocked flow) and hemorrhagic (from the fragile collaterals rupturing).

EDAS aims to replace this inadequate collateral network with a more robust supply routed from outside the skull. Long-term follow-up data support its effectiveness. In a study of adult moyamoya patients in China, EDAS produced satisfactory improvement in clinical status and helped prevent recurrent strokes over the long term.³ In children, results tend to be even more encouraging. A study following 100 pediatric cases found that about 80% of operated brain hemispheres showed good or excellent revascularization on follow-up imaging.⁴

EDAS Versus Direct Bypass

In a direct bypass, the surgeon physically connects the superficial temporal artery to the middle cerebral artery, creating an immediate pipeline. This produces faster perfusion improvement, and brain perfusion imaging has shown significant early gains in the territory supplied by the internal carotid artery after direct bypass, while EDAS did not show the same immediate improvement on the same scans.⁵ That comparison favored direct bypass for adult moyamoya, and some centers consider direct bypass the stronger option when the patient’s vessels are large enough.

But the picture is not as lopsided as it first appears. EDAS is less technically demanding, carries a shorter operative time, and avoids the risk of the anastomosis site clotting or failing in the immediate postoperative period. For children, patients with very small vessels, and patients whose general condition makes a longer, more complex surgery risky, EDAS remains a strong choice. The evidence base has also grown: across 216 EDAS surgeries in one center’s experience, the recurrent stroke rate for patients with intracranial atherosclerotic disease was about 3%, and there was one perioperative death.⁶

Combining Direct and Indirect Bypass

Rather than choosing one or the other, many neurosurgeons now perform both together. The logic is straightforward: the direct bypass provides immediate blood flow, while the EDAS component builds a broader collateral network over months. A study of patients receiving the combined approach found a surgical success rate of 95%, compared with 75% for a control group, along with significantly better blood flow measurements and neurological function scores one month after surgery, without any increase in complications.⁷

What makes this pairing especially interesting is a phenomenon researchers have documented over time: as the indirect collaterals from EDAS mature, the direct bypass graft often shrinks. In a study tracking flow through the direct graft, about 69% of treated hemispheres showed a drop of more than half in graft flow at six months or later, accompanied by prominent growth of indirect collaterals. The direct graft’s flow dropped from roughly 99 mL/min to about 12 mL/min, while angiography showed EDAS-derived vessels expanding to take over the job.⁸ In effect, the direct bypass serves as a bridge until the brain’s own collateral network is ready, at which point the graft quietly becomes less needed. Researchers describe this as “temporally complementary revascularization.”

Beyond Moyamoya: Intracranial Atherosclerosis

One of the more significant developments in recent years is the application of EDAS to intracranial atherosclerotic disease, which is one of the most common causes of stroke worldwide. In this condition, fatty plaques build up inside the brain’s arteries, narrowing them. Medical treatment with blood thinners and aggressive risk-factor management is the standard approach, but some patients continue to have strokes despite best medical therapy.

A phase II trial tested EDAS combined with intensive medical management against medical management alone in patients with symptomatic intracranial artery narrowing. Over a median follow-up of about two years, roughly 10% of the EDAS group experienced a primary endpoint event (stroke or death), compared with about 21% in matched medical-management controls.⁹ Around 89% of the surgical patients showed evidence of new vessel growth, and 86% remained functionally independent. Surgical complications occurred in fewer than 4% of patients, with no intracranial hemorrhages. These results were considered strong enough to justify moving to a phase III trial, meaning EDAS for atherosclerotic disease is still being rigorously tested but has cleared early safety and efficacy hurdles.

Cost-effectiveness analyses have also looked favorable for adding EDAS to medical management in this population, given the reduction in recurrent strokes and associated long-term disability costs.¹⁰

What Drives New Blood Vessel Growth After EDAS

The success of EDAS depends entirely on whether the brain grows adequate new vessels from the transplanted artery. Not every patient does, and researchers have been trying to understand what separates the good responders from the poor ones.

One line of research has focused on endothelial progenitor cells, which are circulating cells that can develop into the cells lining blood vessels. A prospective clinical trial measured these cells in moyamoya patients undergoing EDAS and found that patients who developed strong collateral circulation after surgery had significantly higher counts of these progenitor cells than patients with poor collateral growth. In multivariate analysis, the progenitor cell count was one of the strongest predictors of a good result, alongside age and disease stage.¹¹ This suggests the procedure does not merely create a physical scaffold for vessel growth; it depends on the patient’s biological capacity to build new vessels, which varies from person to person.

On the anatomical side, the size of the superficial temporal artery before surgery and the severity of the underlying vascular occlusion also matter. In adult moyamoya patients, those with a larger donor artery and more complete occlusion of major intracranial vessels were more likely to show strong collateral growth. About 79% of operated hemispheres showed some collateral ingrowth from the artery, but only about 36% reached the highest grade of revascularization.¹² There is an intuitive logic to this: a brain that is more starved for blood has a stronger biological drive to recruit new supply.

Risk Factors and Complications

EDAS is generally considered a low-risk procedure compared with direct bypass, but it is still brain surgery. One complication neurosurgeons watch for closely is cerebral hyperperfusion syndrome, where blood flow to the brain suddenly increases beyond what the tissue can tolerate, sometimes leading to swelling or hemorrhage. In a study of moyamoya patients undergoing revascularization, about 7.5% developed this syndrome, and roughly 2.5% experienced bleeding as a result. Having prominent moyamoya vessels on the surgical side and operating on the left hemisphere were both independent risk factors.¹³

Anesthesia management during EDAS requires particular care because the brain’s blood supply is already compromised. The goal is to maintain stable blood pressure and avoid drops in carbon dioxide or blood oxygen that could provoke a stroke during the operation itself. In the large series of 216 surgeries mentioned earlier, deviations from the anesthesia protocol were extremely rare and did not result in clinical harm.¹⁴

How Surgeons Measure Success

After EDAS, the key question is whether new vessels actually grew. The traditional tool for answering this is the Matsushima grading system, which uses catheter-based angiography to estimate how much of the middle cerebral artery territory is now supplied by the transplanted artery’s offspring vessels. A grade of A or B (covering more than two-thirds of the territory) is considered a good result, and patients who achieve it have fewer ischemic events than those who do not.¹⁵

The Matsushima system has been the standard for decades, but it has a recognized weakness: it is subjective, and different clinicians can assign different grades to the same images.¹⁶ A newer alternative called the Orbital Grading System has shown tighter agreement between raters while correlating well with the Matsushima grades. Its adoption is still in early stages, but it addresses a real practical problem: when clinicians disagree about how well a surgery worked, it becomes harder to compare results across hospitals or decide whether a patient needs additional surgery.

Non-invasive imaging is also gaining ground. Arterial spin-labeling MRI can track changes in brain perfusion without requiring a catheter. In children with moyamoya who underwent indirect revascularization, this technique showed promise in monitoring perfusion changes after surgery, potentially reducing the need for repeated invasive angiograms.¹⁷

What Predicts Long-Term Outcomes in Adults

Quality of collateral formation after EDAS does more than look good on imaging. It predicts whether patients stay well. A study following adult moyamoya patients after EDAS found that poor collateral growth was an independent risk factor for both a bad overall prognosis and a higher rate of subsequent stroke. The other major risk factors were older age, smoking, hypertension, and being significantly disabled at the time of surgery.¹⁸ What this means practically is that EDAS works best when done before the disease has caused major damage and when modifiable risk factors like smoking and blood pressure are well controlled.

Time to surgery after symptom onset matters too. Among pediatric patients, those who had surgery sooner after their first symptoms showed better revascularization on follow-up angiography, and preoperative stroke was associated with worse new vessel growth.¹⁹ The theme across age groups is consistent: earlier intervention gives the brain a better chance to build the new supply it needs.

Cognitive Benefits Beyond Stroke Prevention

Preventing strokes is the headline goal, but EDAS and other indirect revascularization techniques may improve brain function in subtler ways. In children with moyamoya who underwent indirect revascularization, researchers documented improvements in verbal memory after surgery that correlated directly with increased blood flow in the territory of the middle cerebral artery. Patients who showed the strongest perfusion gains on the left side of the brain also showed the greatest improvements in verbal learning and overall intellectual function.²⁰ These gains were tied to longer follow-up intervals, suggesting that cognitive recovery, like vessel growth, is a slow process that unfolds over months and years.

This is a finding that does not always make it into discussions focused narrowly on stroke prevention. Many children with moyamoya experience declining school performance, difficulty concentrating, and memory problems before they are ever diagnosed. The evidence that restoring blood flow can partially reverse these deficits underscores why early diagnosis and timely surgery matter beyond the risk of an obvious stroke event.

Technical Variations on the Theme

EDAS is not one fixed technique. Surgeons have developed several modifications depending on the patient’s anatomy and the territory that needs revascularization. Pial synangiosis, for example, involves suturing the adventitia (outer wall) of the superficial temporal artery directly to the pia mater, the delicate innermost layer covering the brain.²¹ Some centers consider this a refinement of EDAS that brings the artery into closer contact with brain tissue, potentially promoting faster neovascularization.

Another modification, called intradural arteriosynangiosis or IDAS, was developed specifically for pediatric patients who already have some naturally developing collateral vessels. Standard EDAS involves opening the dura widely, which can disrupt these early collaterals. IDAS modifies the technique to preserve existing revascularization while still laying down the transplanted artery.²² When a moyamoya patient is first seen, their brain may already have begun compensating on its own, and the surgeon has to balance encouraging new growth with protecting what nature has already started.

For patients whose disease affects the front of the brain more than the sides, some surgeons add a separate frontal procedure called encephalogaleo(periosteal)synangiosis, which transplants tissue from the scalp’s galea layer onto the frontal brain surface. In one series, this combined approach produced measurable improvement in blood flow and reserve capacity in the frontal brain territory in more than half of operated patients.²³ The flexibility of indirect revascularization to target different regions by repositioning different tissue sources is one of its underappreciated strengths.